Cargando…
Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant
The phase III Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors Trial (BENEFIT‐EXT) study compared more or less intensive belatacept‐based immunosuppression with cyclosporine (CsA)–based immunosuppression in recipients of extended c...
Autores principales: | Florman, S., Becker, T., Bresnahan, B., Chevaile‐Ramos, A., Carvalho, D., Grannas, G., Muehlbacher, F., O'Connell, P. J., Meier‐Kriesche, H. U., Larsen, C. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215636/ https://www.ncbi.nlm.nih.gov/pubmed/27232116 http://dx.doi.org/10.1111/ajt.13886 |
Ejemplares similares
-
Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study
por: Durrbach, A., et al.
Publicado: (2016) -
Posttransplant reduction in preexisting donor‐specific antibody levels after belatacept‐ versus cyclosporine‐based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT‐EXT
por: Bray, R. A., et al.
Publicado: (2018) -
De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT studies
por: Bray, R. A., et al.
Publicado: (2018) -
Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas
por: Sarrión, P., et al.
Publicado: (2013) -
Analysis of mutations in EXT1 and EXT2 in Brazilian patients with multiple osteochondromas
por: Santos, Savana C. L., et al.
Publicado: (2018)